Skip to main content

ferric maltol (Feraccru®)


Status: Recommended with restrictions

Ferric maltol (Feraccru®) is recommended as an option for restricted use within NHS Wales.

Ferric maltol (Feraccru®) is licensed for the treatment of iron deficiency in adults.

Ferric maltol (Feraccru®) is restricted for use in adult patients with inflammatory bowel disease (IBD) who have mild to moderate iron deficiency anaemia (IDA) and have failed on, or are intolerant to, standard oral iron products and are considered suitable for intravenous iron.

Ferric maltol (Feraccru®) is not recommended for use within NHS Wales outside of this subpopulation.

 Appraisal report: ferric maltol (Feraccru) 5116 (PDF, 325Kb)
 Final Recommendation: ferric maltol (Feraccru) 5116 (PDF, 421Kb)
 Equality impact assessment ferric maltol (PDF, 99Kb)

Medicine details

Medicine name ferric maltol (Feraccru®)
Formulation 30 mg hard capsule
Reference number 5116

Treatment of iron deficiency in adults

Company Norgine Pharmaceuticals Ltd
BNF chapter Nutrition & blood
Submission type Resubmission
Status Recommended with restrictions
Advice number 1922
NMG meeting date 07/09/2022
AWMSG meeting date 18/10/2022
Date of issue 07/11/2022
Follow AWTTC: